Wells Frargo analysts found that in June, pharma companies raised the prices of 106 medicines by an average of 27 percent. Included in the price hikes was a 909 percent increase for a generic antidiuretic manufactured by a subsidiary of Teva Pharmaceuticals and a 399 percent increase on two drugs made by Epic Pharma.
According to Wells Fargo Analyst David Maris, pharmaceutical companies have been more aggressive with price hikes after a hiatus in criticism.
“To us, it appears now that the criticism from politicians and the president has quieted down, companies are more aggressively and broadly pursuing drug price increases again,” he told Bloomberg. “We are not so confident that the lull in criticism will continue and could foresee more negative headlines in the coming months.”
More articles on pharmacy:
Judge blocks HHS rule requiring drug prices in TV ads
Nation’s 1st prescription drug affordability board goes into effect
11 healthcare pharma leaders offer advice on controlling drug spend
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
